Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients

Ann Oncol. 2019 May 1;30(5):663-665. doi: 10.1093/annonc/mdz119.

¹ CZ Health Insurance, Tilburg.
² National Health Care Institute (Zorginstituut Nederland), Diemen.
³ Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Center for Personalised Cancer Treatment (CPCT).
⁴ Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam.
⁵ Division of Medical Oncology, Leiden University Medical Center, Leiden.
⁶ Division of Medical Oncology, Amsterdam University Medical Center, Cancer Center Amsterdam, Amsterdam.
⁷ Department of Biometrics, Netherlands Cancer Institute, Amsterdam.
⁸ Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam; Department of Health Technology and Services Research, University of Twente, Enschede.
⁹ Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam; Department of Health Technology and Services Research, University of Twente, Enschede; Rijnstate Hospital, Arnhem.
¹⁰ Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam; Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
¹¹ Center for Personalised Cancer Treatment (CPCT); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam. Electronic address: e.voest@nki.nl.

No abstract available

Publication types